Premium
Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications
Author(s) -
Alison L Jones,
Kenneth J. Simpson
Publication year - 1999
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.1999.00454.x
Subject(s) - ecstasy , mdma , amphetamine , medicine , hallucinogen , pharmacology , psychiatry , dopamine
The social use of ecstasy (methylenedioxymethampheta‐mine, MDMA) and amphetamines is widespread in the UK and Europe, and they are popularly considered as ‘safe’. However, deaths have occurred and hepatotox‐icity has featured in many cases of intoxication with amphetamine or its methylenedioxy analogues such as ecstasy. Recreational use of these drugs presents an important but often concealed cause of hepatitis or acute liver failure, particularly in young people. The patterns of liver damage and multiple putative mechanisms of injury are discussed. Recognition of the aetiological agent requires a high index of suspicion. Optimum management of the resultant liver damage, including the controversial role of liver transplantation for fulminant hepatic failure, is also discussed.